Novel cell membrane cation transporter associated with platinum therapy resistance in pancreatic adenocarcinoma identified through CRISPR/Cas9 loss-of- function screen

MLA

Joshua T. Mendell, et al. “Novel Cell Membrane Cation Transporter Associated with Platinum Therapy Resistance in Pancreatic Adenocarcinoma Identified through CRISPR/Cas9 Loss-of- Function Screen.” HPB, vol. 20, Mar. 2018, p. S25. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........9d518dae86907a3ea45b9c9aeb1fe068&authtype=sso&custid=ns315887.

APA

Joshua T. Mendell, Y. Xie, B. Chen, Epameinondas Dogeas, & Mathew M. Augustine. (2018). Novel cell membrane cation transporter associated with platinum therapy resistance in pancreatic adenocarcinoma identified through CRISPR/Cas9 loss-of- function screen. HPB, 20, S25.

Chicago

Joshua T. Mendell, Y. Xie, B. Chen, Epameinondas Dogeas, and Mathew M. Augustine. 2018. “Novel Cell Membrane Cation Transporter Associated with Platinum Therapy Resistance in Pancreatic Adenocarcinoma Identified through CRISPR/Cas9 Loss-of- Function Screen.” HPB 20 (March): S25. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........9d518dae86907a3ea45b9c9aeb1fe068&authtype=sso&custid=ns315887.